Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199192 · ClinicalTrials.gov registry record · Phase 4
Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Not yet
- Registry status
- Phase 4
- Development phase
- 3,000
- Enrollment target
NCT07199192: Clinical Trial Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT07199192 is a Phase 4 study that has not yet begun recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,000 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (479% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07199192, a Phase 4 study, has not yet begun recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults hospitalized with severe acute respiratory infection and hypoxemia.
Primary Outcome
defined as death from any cause between randomization (Day 0) and 28 days (the end of Study Day 27. Outcome ascertainment ends at hospital discharge.
Interventions
- DRUG Corticosteroid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 4 |
What is known before NCT07199192 opens enrollment
NCT07199192 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (479% higher).
The record links to 0 conditions, and to 1 intervention - of which Corticosteroid is the first listed.
NCT07199192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07199192 about?
NCT07199192 is a clinical study titled "Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial". Multicenter, parallel-group, randomized clinical trial comparing the administration of systemic corticosteroids at a dose equivalent to 40 mg of prednisolone per day for 7 days vs no corticosteroid administration among adults hospitalized with severe acute respiratory infection and hypoxemia.
What is the current status of trial NCT07199192?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 3,000 participants. The study started on 2026-03-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07199192?
The interventions under investigation include: Corticosteroid (DRUG).
Who is sponsoring clinical trial NCT07199192?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07199192's enrollment target sits among peer trials
3,000 25th of 2000 higher than 1,976 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI